Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 4, pp 935–944

Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients

  • I. G. Hwang
  • J. S. Jang
  • J. H. Do
  • J. H. Kang
  • G. W. Lee
  • S. Y. Oh
  • H. C. Kwon
  • H. J. Jun
  • H. Y. Lim
  • S. Lee
  • K. C. Chi
  • S. J. Lee
Original Article

DOI: 10.1007/s00280-011-1558-3

Cite this article as:
Hwang, I.G., Jang, J.S., Do, J.H. et al. Cancer Chemother Pharmacol (2011) 68: 935. doi:10.1007/s00280-011-1558-3

Abstract

Purpose

The aim of this study is to evaluate the effect of excision repair cross-complementation group 1 (ERCC1) expression on treatment outcomes in advanced biliary tract adenocarcinoma (ABTA) patients treated with platinum-based chemotherapy.

Methods

One hundred and six patients with histologically confirmed adenocarcinoma of biliary tract were enrolled at 5 institutions in South Korea between January 2002 and September 2008. Of 106 patients, 93 were assessed by immunohistochemistry from tissue specimens. Sixty-five patients were treated with cisplatin-based regimens and the other 28 treated with oxaliplatin-based ones.

Results

For total study population, no significant differences were noted in progression-free survival (PFS) and overall survival (OS) between ERCC1-negative and ERCC1-positive patients, respectively (4.2 vs. 2.9 months, p = 0.116; 7.0 vs. 7.8 months, p = 0.143). In patients treated with cisplatin-based regimens, median PFS and OS were significantly longer in ERCC1-negative group than in ERCC1-positive group, respectively (4.6 vs. 1.9 months, p = 0.014; 9.1 vs. 7.9 months, p = 0.017). Disease control rate (DCR) was better in patients with ERCC1 negative than in patients with ERCC1 positive (p = 0.048). On the other hand, in patients treated with oxaliplatin-containing regimens, median PFS and OS tended to be longer in ERCC1-positive group, but these did not reach statistical significances. Response rate was better in patients with ERCC1 positive (p = 0.005).

Conclusions

ERCC1 shows a significant prognostic value in ABTA patients treated with cisplatin. A survival benefit was observed in ERCC1-negative patients from cisplatin-containing chemotherapy but not from oxaliplatin-containing ones. The action mechanism of ERCC1 on cisplatin may be different from that on oxaliplatin.

Keywords

Advanced biliary tract adenocarcinomaERCC1CisplatinOxaliplatin

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • I. G. Hwang
    • 1
  • J. S. Jang
    • 1
  • J. H. Do
    • 1
  • J. H. Kang
    • 2
  • G. W. Lee
    • 2
  • S. Y. Oh
    • 3
  • H. C. Kwon
    • 3
  • H. J. Jun
    • 4
  • H. Y. Lim
    • 5
  • S. Lee
    • 6
  • K. C. Chi
    • 7
  • S. J. Lee
    • 1
  1. 1.Department of Internal MedicineChung-Ang University College of MedicineDongjak-guRepublic of Korea
  2. 2.Department of MedicineGyeongsang National University College of MedicineJinju-siRepublic of Korea
  3. 3.Department of MedicineDong-A University College of MedicineSeo-guRepublic of Korea
  4. 4.Department of MedicineMyongi Hopital, Kwandong University College of MedicineDeokyang-guRepublic of Korea
  5. 5.Department of MedicineSamsung Medical Center, Sungkyunkwan University School of MedicineKangnam-guRepublic of Korea
  6. 6.Department of PathologyKangwon National University Hospital, Kangwon National University School of MedicineChunchonRepublic of Korea
  7. 7.Department of SurgeryChung-Ang University College of MedicineDongjak-guRepublic of Korea